Sign in
Active, not recruitingNo phase

Effect of Defocus in Soft Contact Lenses on Internal Retinal Vascularization

Key facts

Who runs it
Université de Montréal
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
25 people, planned
Started
25 Jun 2024
Ended
30 Mar 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Experimental: Myopic defocus soft lens design (MDSL)
  • Active Comparator: Single vision soft lens design (SVSL
Record updated
27 March 2025

Who can take part

Age
18 years to 35 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • · Astigmatism ≤ 1.00 D; Myopia between -0.50 and -4.00D; Aged between 18 and 35; Binocular acuity of 6/6 or better

Who cannot take part

  • · Recent intake (< 3 months) of medication affecting blood pressure (e.g. hypotensive, anovulant, CNS stimulant, etc.); Corneal dystrophy or irregularity; Use of topical ocular medications; Smoking (tobacco or marijuana); Have contraindications to wearing soft contact lenses; Being currently under myopia control treatment or had been under control in the last 3 months; Being pregnant or breast-feeding; History of refractive surgery; Addiction to drugs or alcohol

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to gain a better understanding of the retinal vascular changes that occur in response to the optical effect of a myopic defocus daily disposable soft contact lens (MDSL) in a group of healthy young myopic adults (18-35 years; myopia -1.00D to -4.00D; all genders). It will also learn about the acceptance of this visual correction modality compared to regular contact lenses.

Read full original descriptionShow less

The main questions to be answered are:

* To evaluate changes in retinal blood flow by visualizing retinal vascular density in the superficial and deep plexus after one week of MDSL wear. * To evaluate changes in choroidal thickness at the macular level after one week of MDSL wear. * To evaluate the visual comfort provided by this MDSL design using a questionnaire.

Researchers will compare the MDSL to a daily disposable single vision soft lens (SVSL) used to correct myopia to determine if the addition of a defocus area makes a difference in the retinal response to the visual signal.

Participants will be required to

* Wear both MDSL and SVSL for one week each, in a random order. * Read letters to measure visual acuity * Have a deep scan of their retina with an optical coherence tomography (OCT) device * Rate the comfort and vision provided by both devices using a questionnaire.

The 2 groups in the trial

  • Myopic defocus soft lens design (MDSL)Treatment being tested

    This arm involves the wear of a daily disposable soft contact lens (nesofilcon A) designed with a myopic defocus zone. This is a 14.2mm total diameter lens with a 4.2mm central zone for distance vision correction. This is followed by an abrupt transition zone of 1.2mm with no optical power. Then a higher convex power zone covers the surface to the edge of the optical zone (8mm). The rest of the lens (up to 14.2 mmOAD) supports the lens on the eye surface and has no power nor refractive effect. The power of the add area is calibrated to the central power to achieve a net add power of +5D. For example: -1.00D central power is surrounded by a +6D convex area; -2D is surrounded by a +7D area, and so on.)

    Treatment: Experimental: Myopic defocus soft lens design (MDSL)

  • Single vision soft lens design (SVSL)Existing treatment, for comparison

    This arm involves the wear of a daily disposable soft contact lens (nesofilcon A) designed as a regular optical device to compensate for refractive error. In the case of this study, this lens will be made available from -1.00D to -4.00D. This lens is already in regular use in the US (K113703) and Canadian markets. Its design includes a central optical zone of 8mm that is powered to correct distance vision. The rest of the lens is supported on the ocular surface and has no power.

    Treatment: Active Comparator: Single vision soft lens design (SVSL

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
27 March 2025